Atmo Biosciences is ramping up manufacture of its third generation Atmo Gas Capsule at Planet Innovation’s ISO 13485:2016 certified medtech manufacturing facility.

Hundreds of capsules are being manufactured in coming months for use in multiple clinical trials, including a study that is underway at the University of Gothenburg in Sweden to better understand the impact of carbohydrates on people with Irritable Bowel Syndrome (IBS).

The ground-breaking ingestible gas-sensing capsule is a digital biomarker for gastrointestinal health. Once swallowed, it continuously profiles clinically important gases as it passes through the gastrointestinal tract, transmitting the data to the cloud in real-time for aggregation and analysis. The latest generation of the capsule offers improved performance and improved manufacturability.

Atmo Biosciences CEO Mal Hebblewhite said: “Atmo is entering an exciting phase, as we begin new studies using the third generation Atmo Gas Capsule. Our technology enables researchers to gain a better understanding of gut health and microbiome function, enabling better diagnosis and treatment for disorders such as IBS.”

Want to know how the Atmo Gas Capsule could help your research? Get in touch.